Praxis Precision Medicines

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2015-09-22

Employees: 82

Market Cap: $950.3M

Website: http://www.praxismedicines.com

Introduction: Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Clinical Trials

Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

Phase 3

Recruiting

Conditions: Essential Tremor

Interventions: Drug: 60 mg ulixacaltamide
Drug: Placebo

First Posted Date: 2023-10-17

Last Posted Date: 2024-04-05

Lead Sponsor: Praxis Precision Medicines

Target Recruit Count: 600

Registration Number: NCT06087276

Locations: 🇺🇸
United BioSource LLC, Morgantown, West Virginia, United States

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

Phase 2

Recruiting

Conditions: SCN2A Encephalopathy
SCN8A Encephalopathy

First Posted Date: 2023-04-19

Last Posted Date: 2024-01-10

Lead Sponsor: Praxis Precision Medicines

Target Recruit Count: 20

Registration Number: NCT05818553

Locations: 🇪🇸
Praxis Research Site, Madrid, Spain

A Clinical Trial of PRAX-222 in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy

Phase 1

Recruiting

Conditions: SCN2A-DEE
Epilepsy

Interventions: Procedure: Placebo
Drug: PRAX-222 - Fixed Doses
Drug: PRAX-222 - Initial Dose
Drug: PRAX-222 - Initial Ascending Doses
Drug: PRAX-222 - Optional Ascending Doses

First Posted Date: 2023-02-21

Last Posted Date: 2024-10-04

Lead Sponsor: Praxis Precision Medicines

Target Recruit Count: 60

Registration Number: NCT05737784

Locations: 🇺🇸
Le Bonheur Childrens Hospital, Memphis, Tennessee, United States
🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil

A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy

Completed

Conditions: SCN2A-DEE
Epilepsy

First Posted Date: 2022-06-07

Last Posted Date: 2024-01-10

Lead Sponsor: Praxis Precision Medicines

Target Recruit Count: 5

Registration Number: NCT05407727

Locations: 🇺🇸
Praxis Research Site, Atlanta, Georgia, United States

A Clinical Trial of PRAX-114 in Participants With Essential Tremor

Phase 2

Withdrawn

Conditions: Essential Tremor

Interventions: Drug: 10 mg PRAX-114, 20 mg PRAX-114, and Placebo
Drug: 10 mg PRAX-114 or 20 mg PRAX-114

First Posted Date: 2022-05-24

Last Posted Date: 2022-11-30

Lead Sponsor: Praxis Precision Medicines

Registration Number: NCT05387642

Locations: 🇺🇸
Praxis Research Site, Kirkland, Washington, United States

A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder

Phase 2

Terminated

Conditions: Post-traumatic Stress Disorder
Stress Disorder
Mental Disorder
Post Traumatic Stress Disorder
Stress Disorders, Post-Traumatic
Trauma and Stressor Related Disorders